261 related articles for article (PubMed ID: 27442383)
1. Molecular Response in Patients with Chronic Myeloid Leukemia Treated with Imatinib - Single Centre Experience.
Pavkovic M; Angelkovic R; Popova-Simjanovska M; Genadieva-Stavric S; Cevreska L; Stojanovic A
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2015; 36(2):179-86. PubMed ID: 27442383
[TBL] [Abstract][Full Text] [Related]
2. Analysis of Survival of Patients with Chronic Myeloid Leukemia Treated with Imatinib in the Last 15 Years in Lebanon.
Massoud M; Sakr R; Kerbage F; Makdissi J; Hawi J; Rached L; Nasr F; Chahine G
Clin Lymphoma Myeloma Leuk; 2017 Jul; 17S():S111-S115. PubMed ID: 28760296
[TBL] [Abstract][Full Text] [Related]
3. Molecular monitoring of imatinib in chronic myeloid leukemia patients in complete cytogenetic remission: does achievement of a stable major molecular response at any time point identify a privileged group of patients? A multicenter experience in Argentina and Uruguay.
Pavlovsky C; Giere I; Moiraghi B; Pavlovsky MA; Aranguren PN; García J; Fernandez I; Bengió R; Milone J; Labanca V; Uriarte R; Lombardi V; Reinoso FG; Magariños AE; Martinez L; Murro H; Lastiri F; Pavlovsky S
Clin Lymphoma Myeloma Leuk; 2011 Jun; 11(3):280-5. PubMed ID: 21658656
[TBL] [Abstract][Full Text] [Related]
4. Generic imatinib in the treatment of chronic myeloid leukemia: two years' experience in Latvia.
Lejniece S; Udre I; Rivkina A
Exp Oncol; 2017 Jul; 39(2):151-154. PubMed ID: 29483494
[TBL] [Abstract][Full Text] [Related]
5. Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial.
Cortes JE; Gambacorti-Passerini C; Deininger MW; Mauro MJ; Chuah C; Kim DW; Dyagil I; Glushko N; Milojkovic D; le Coutre P; Garcia-Gutierrez V; Reilly L; Jeynes-Ellis A; Leip E; Bardy-Bouxin N; Hochhaus A; Brümmendorf TH
J Clin Oncol; 2018 Jan; 36(3):231-237. PubMed ID: 29091516
[TBL] [Abstract][Full Text] [Related]
6. Molecular monitoring of response to imatinib (Glivec) in chronic myeloid leukemia patients: experience at a tertiary care hospital in Saudi Arabia.
Khalil SH; Abu-Amero KK; Al Mohareb F; Chaudhri NA
Genet Test Mol Biomarkers; 2010 Feb; 14(1):67-74. PubMed ID: 19943786
[TBL] [Abstract][Full Text] [Related]
7. Planned Pregnancy in Female Patients with Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitor Therapy.
Dou X; Qin Y; Huang X; Jiang Q
Oncologist; 2019 Nov; 24(11):e1141-e1147. PubMed ID: 31186377
[TBL] [Abstract][Full Text] [Related]
8. Diagnosis and Monitoring of Chronic Myeloid Leukemia: Chiang Mai University Experience.
Tantiworawit A; Kongjarern S; Rattarittamrong E; Lekawanvijit S; Bumroongkit K; Boonma N; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Norasetthada L
Asian Pac J Cancer Prev; 2016; 17(4):2159-64. PubMed ID: 27221912
[TBL] [Abstract][Full Text] [Related]
9. Comparative Effectiveness of Newer Tyrosine Kinase Inhibitors Versus Imatinib in the First-Line Treatment of Chronic-Phase Chronic Myeloid Leukemia Across Risk Groups: A Systematic Review and Meta-Analysis of Eight Randomized Trials.
Yun S; Vincelette ND; Segar JM; Dong Y; Shen Y; Kim DW; Abraham I
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e85-94. PubMed ID: 27101984
[TBL] [Abstract][Full Text] [Related]
10. Chronic myeloid leukemia patients in Tunisia: epidemiology and outcome in the imatinib era (a multicentric experience).
Ben Lakhal R; Ghedira H; Bellaaj H; Ben Youssef Y; Menif S; Manai Z; Bedoui M; Lakhal A; M'Sadek F; Elloumi M; Khélif A; Ben Romdhane N; Laatiri MA; Ben Othmen T; Meddeb B
Ann Hematol; 2018 Apr; 97(4):597-604. PubMed ID: 29305630
[TBL] [Abstract][Full Text] [Related]
11. Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?
Kong JH; Winton EF; Heffner LT; Chen Z; Langston AA; Hill B; Arellano M; El-Rassi F; Kim A; Jillella A; Kota VK; Bodó I; Khoury HJ
Cancer; 2017 Jul; 123(13):2482-2488. PubMed ID: 28241101
[TBL] [Abstract][Full Text] [Related]
12. Real-world Imatinib Mesylate Treatment in Patients with Chronic Myeloid Leukemia: The Importance of Molecular Monitoring and the Early Molecular Response.
Ferreira APS; Seguro FS; Abdo ARN; Santos FM; Maciel FVR; Nardinelli L; Giorgi RR; Ruiz ARL; Ferreira MPS; Rego EM; Rocha V; Bendit I
Ann Hematol; 2023 Jul; 102(7):1761-1771. PubMed ID: 37052662
[TBL] [Abstract][Full Text] [Related]
13. Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.
Shiseki M; Yoshida C; Takezako N; Ohwada A; Kumagai T; Nishiwaki K; Horikoshi A; Fukuda T; Takano H; Kouzai Y; Tanaka J; Morita S; Sakamoto J; Sakamaki H; Inokuchi K
Int J Clin Oncol; 2017 Oct; 22(5):972-979. PubMed ID: 28550414
[TBL] [Abstract][Full Text] [Related]
14. Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months.
Casado LF; García-Gutiérrez JV; Massagué I; Giraldo P; Pérez-Encinas M; de Paz R; Martínez-López J; Bautista G; Osorio S; Requena MJ; Palomera L; Peñarrubia MJ; Calle C; Hernández-Rivas JÁ; Burgaleta C; Maestro B; García-Ormeña N; Steegmann JL
Cancer Med; 2015 Jul; 4(7):995-1002. PubMed ID: 25756742
[TBL] [Abstract][Full Text] [Related]
15. The predictive value of early molecular response in chronic myeloid leukaemia patients treated with imatinib in a single real-world medical centre in a developing country.
Bee PC; Sekaran V; Ng RR; Kweh TY; Gan GG
Singapore Med J; 2017 Mar; 58(3):150-154. PubMed ID: 27029807
[TBL] [Abstract][Full Text] [Related]
16. Relationship between SLCO1B3 and ABCA3 polymorphisms and imatinib response in chronic myeloid leukemia patients.
de Lima LT; Bueno CT; Vivona D; Hirata RD; Hirata MH; Hungria VT; Chiattone CS; Zanichelli MA; Chauffaille Mde L; Guerra-Shinohara EM
Hematology; 2015 Apr; 20(3):137-42. PubMed ID: 25056761
[TBL] [Abstract][Full Text] [Related]
17. Which method better evaluates the molecular response in newly diagnosed chronic phase chronic myeloid leukemia patients with imatinib treatment, BCR-ABL(IS) or log reduction from the baseline level?
Qin YZ; Jiang Q; Jiang H; Li JL; Li LD; Zhu HH; Lai YY; Lu XJ; Liu YR; Jiang B; Huang XJ
Leuk Res; 2013 Sep; 37(9):1035-40. PubMed ID: 23810191
[TBL] [Abstract][Full Text] [Related]
18. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
[TBL] [Abstract][Full Text] [Related]
19. Hematological and molecular response evaluation of CML patients on imatinib.
Gupta A; Prasad K
J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of BCR-ABL T315I Mutation in Malaysian Patients with Imatinib-Resistant Chronic Myeloid Leukemia.
Mat Yusoff Y; Abu Seman Z; Othman N; Kamaluddin NR; Esa E; Zulkiply NA; Abdullah J; Zakaria Z
Asian Pac J Cancer Prev; 2018 Dec; 19(12):3317-3320. PubMed ID: 30583336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]